Pfizer: rescruiting for gene therapy
(CercleFinance.com) - Pfizer and Sangamo Therapeutics have announced the reopening of enrollment in the AFFINE Phase 3 trial evaluating giroctocogen fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A.
Trial sites will begin to resume enrolment this month, with dosing expected to resume in October.
All trial sites are expected to be active by the end of 2022 and results from the pivotal study are expected in the first half of 2024.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Trial sites will begin to resume enrolment this month, with dosing expected to resume in October.
All trial sites are expected to be active by the end of 2022 and results from the pivotal study are expected in the first half of 2024.
Copyright (c) 2022 CercleFinance.com. All rights reserved.